Kura Oncology Inc

KURANASDAQ · USD
10.44USD-0.32 (-2.98%)
159

Kura Oncology Inc (KURA) Straddle

KURA straddle scan found 29 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 63.9%.

Read more

Trading a KURA straddle lets you take a pure volatility position on Kura Oncology Inc without committing to a direction. Kura Oncology Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate KURA straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on KURA profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Kura Oncology Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the KURA straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the KURA straddle is the cleanest expression of that view. Our scanner prices every KURA straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a KURA straddle into a catalyst or short a KURA straddle to harvest decay, the options straddle setups that matter are all in one place.

Jan 19, 202922.00$14.3584815%63.9%$36.35$7.650
Oct 16, 202613.00$1.952215%60.5%$14.95$11.0583
Jan 19, 202920.00$13.4584815%59.6%$33.45$6.550
Jan 19, 202917.00$11.4584815%56.0%$28.45$5.550
Apr 16, 202714.00$5.3320415%54.4%$19.33$8.6831
Apr 16, 202715.00$6.1520415%53.2%$21.15$8.85100
Jan 15, 202715.00$5.1811315%52.8%$20.18$9.83290
Jan 21, 202817.00$10.0348415%52.7%$27.03$6.980
Apr 16, 202716.00$7.0020415%52.5%$23.00$9.0029
Apr 16, 202713.00$5.0020415%51.3%$18.00$8.00147

As of September 25, 2026

Find the right straddle before volatility moves

Track KURA straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial